AC Immune starts final cohort in alzheimer's drug trial

April 30, 2026 7:01 AM

AC Immune SA (NASDAQ: ACIU) announced it has dosed the first patients in Cohort AD4 of its ongoing Phase 1b/2 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found